BioCentury | Mar 2, 2018
Clinical News

Asana reports Phase Ib data for ASN002 in atopic dermatitis

...71%, respectively. Data were presented at the American Academy of Dermatology meeting in San Diego. Asana...
...is also in Phase I/II testing to treat non-Hodgkin's lymphoma (NHL) and advanced solid tumors. Asana BioSciences LLC...
...Area and Severity Index (EASI) score Status: Phase Ib data Milestone: Start Phase IIb (2018) Allison Johnson ASN002 Asana BioSciences LLC Janus...
BioCentury | Jun 16, 2017
Clinical News

Asana reports Phase I/II data for SYK/JAK inhibitor ASN002 to treat cancer

...follicular lymphoma. ASN002 is a dual spleen tyrosine kinase (SYK) and Janus kinase (JAK) inhibitor. Asana BioSciences LLC...
...Phase II); safety and pharmacokinetics Status: Phase I/II data Milestone: NA Julian Zhu ASN002 American Society of Clinical Oncology Asana BioSciences LLC Janus...
BioCentury | Feb 3, 2017
Clinical News

ASN003: Ph I started

...phosphatase and tensin homolog deleted on chromosome ten ( PTEN ; MMAC1 ; TEP1) mutation. Asana BioSciences LLC...
...of non-measurable tumor lesions and appearance of new lesions Status: Phase I started Milestone: NA Chris Lieu Asana BioSciences LLC BRAF Phosphoinositide...
BioCentury | May 16, 2016
Financial News

Asana Medical completes venture financing

Asana Medical Inc. , Miami Lakes, Fla. Business: Autoimmune, Gastrointestinal Date completed: 2016-05-10 Type: Venture financing Raised: $1.2 million Note: The financing comprises convertible promissory notes. WIR Staff autoimmune Gastrointestinal...
BioCentury | Oct 27, 2015
Company News

Management tracks

...professor at Lund University Hospital and was a part-time senior scientist at NeuroVive. Oncology company Asana BioSciences LLC...
BioCentury | Jul 27, 2015
Company News

University of Pittsburgh, Asana Medical deal

...The university granted Asana exclusive, worldwide rights to multiple patents and patent applications covering methods and...
...extracellular matrix-derived gels. Asana will initially focus on developing a treatment for ulcerative colitis (UC). Asana’s...
...not respond to inquiries about financial terms and ECMH. University of Pittsburgh , Pittsburgh, Pa. Asana...
BioCentury | Jun 16, 2014
Company News

Asana, Endo deal

...Newco Asana acquired the early stage branded pharmaceutical discovery platform of Endo's Endo Pharmaceuticals Inc. subsidiary...
...development for prostate cancer, but the companies did not disclose a timeline for clinical testing. Asana...
...strategic alternatives for its branded pharmaceutical early stage discovery platform (see BioCentury, June 10, 2013). Asana BioSciences LLC...
Items per page:
1 - 7 of 7
BioCentury | Mar 2, 2018
Clinical News

Asana reports Phase Ib data for ASN002 in atopic dermatitis

...71%, respectively. Data were presented at the American Academy of Dermatology meeting in San Diego. Asana...
...is also in Phase I/II testing to treat non-Hodgkin's lymphoma (NHL) and advanced solid tumors. Asana BioSciences LLC...
...Area and Severity Index (EASI) score Status: Phase Ib data Milestone: Start Phase IIb (2018) Allison Johnson ASN002 Asana BioSciences LLC Janus...
BioCentury | Jun 16, 2017
Clinical News

Asana reports Phase I/II data for SYK/JAK inhibitor ASN002 to treat cancer

...follicular lymphoma. ASN002 is a dual spleen tyrosine kinase (SYK) and Janus kinase (JAK) inhibitor. Asana BioSciences LLC...
...Phase II); safety and pharmacokinetics Status: Phase I/II data Milestone: NA Julian Zhu ASN002 American Society of Clinical Oncology Asana BioSciences LLC Janus...
BioCentury | Feb 3, 2017
Clinical News

ASN003: Ph I started

...phosphatase and tensin homolog deleted on chromosome ten ( PTEN ; MMAC1 ; TEP1) mutation. Asana BioSciences LLC...
...of non-measurable tumor lesions and appearance of new lesions Status: Phase I started Milestone: NA Chris Lieu Asana BioSciences LLC BRAF Phosphoinositide...
BioCentury | May 16, 2016
Financial News

Asana Medical completes venture financing

Asana Medical Inc. , Miami Lakes, Fla. Business: Autoimmune, Gastrointestinal Date completed: 2016-05-10 Type: Venture financing Raised: $1.2 million Note: The financing comprises convertible promissory notes. WIR Staff autoimmune Gastrointestinal...
BioCentury | Oct 27, 2015
Company News

Management tracks

...professor at Lund University Hospital and was a part-time senior scientist at NeuroVive. Oncology company Asana BioSciences LLC...
BioCentury | Jul 27, 2015
Company News

University of Pittsburgh, Asana Medical deal

...The university granted Asana exclusive, worldwide rights to multiple patents and patent applications covering methods and...
...extracellular matrix-derived gels. Asana will initially focus on developing a treatment for ulcerative colitis (UC). Asana’s...
...not respond to inquiries about financial terms and ECMH. University of Pittsburgh , Pittsburgh, Pa. Asana...
BioCentury | Jun 16, 2014
Company News

Asana, Endo deal

...Newco Asana acquired the early stage branded pharmaceutical discovery platform of Endo's Endo Pharmaceuticals Inc. subsidiary...
...development for prostate cancer, but the companies did not disclose a timeline for clinical testing. Asana...
...strategic alternatives for its branded pharmaceutical early stage discovery platform (see BioCentury, June 10, 2013). Asana BioSciences LLC...
Items per page:
1 - 7 of 7